Indeed. The portfolio is very impressive. The indications are massive. The orphan strategy out of the gates is smart. The diversity of products across diagnostics, therapeutics, and discovery with Phenoguard is amazing. If AMBS can now turn on the revenue machine with Lympro then AMBS will have turned a valuable corner.